A2-73 as a therapeutic for insomnia, anxiety and agitation
US2018360796A1
Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease
EP3638225A1
Anavex2-73 for the treatment of alzheimer's disease
EP3407880A1
Neurodevelopmental disorder therapy
WO2017013498A2
Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions
CN107708687A
The enantiomer of the furylamine of 2,2 diphenyl of tetrahydrochysene N, N dimethyl 3（ANAVEX2‑73）And its purposes in treatment Alzheimer's disease and other diseases by the regulations of σ 1
CA2964520A1
A19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy
WO2013008044A1
Synthesis of (+) and (-) 1 -(5,5-diphenyltetrahydrofuran-3- yl)-n,n-dimethylmethanamine, (+) and (-) 1-(2,2-diphenyltetrahydrofuran-3-yl)-n,n- dimethylmethanamine and (+) and (-) 1-(2,2- dffhenyltetrahydrofuran-3-yl)-n-metihylmethanamine
GR1005865B
NEW SIGMA LIGANDS with anti-apoptotic and/or pro-apoptotic action on the cells biochemical mechanisms and neuroprotective, anti-cancer, anti-metastatic, and anti-chronic inflammatory properties.
